04/08/2026
🚀 A Potential Breakthrough in Graves’ Disease Treatment. “We may be witnessing the beginning of a new treatment paradigm for Graves’ Disease.”
What if we could treat Graves’ Disease at its source — not just manage it?
On August 29, 2025, I performed what is, to the best of my knowledge, the first application of nanosecond Pulsed Field Ablation (nPULSE) to the entire thyroid gland for Graves’ Disease.
The concept:
👉 Target the intrathyroidal immune drivers of disease
👉 Disrupt antigen-presenting cells and lymphocyte activity
👉 Use non-thermal electroporation for organ-level immune modulation
đź“Š Early Clinical Experience (n=8):
Across the first 8 patients treated, we are observing a consistent and significant downward trend in TRAb and TSI levels, along with progressive normalization of thyroid hormone levels.
In the index case:
TRAb declined from 14.6 → 1.48 (normalized) within ~3 months.
These early findings suggest that nPULSE may offer a novel, minimally invasive pathway to modulating autoimmune thyroid disease.
No radioactive iodine.
No surgery.
A targeted, outpatient procedure.
⚠️ This represents an early clinical experience and requires further validation, larger studies, and long-term follow-up.
But if these results continue to hold…
This could represent a paradigm shift in the treatment of Graves’ Disease.
🔬⚡📉
More data to come.
ThyroidAblation nPULSE Electroporation AutoimmuneDisease Hyperthyroidism ClinicalResearch MinimallyInvasive FutureOfMedicine PhysicianInnovation Medicine
